Glenmark Life Sciences IPO will be Open Date On 27 July 2021 and closed on 29 July 2021. Glenmark Life Sciences IPO GMP Kostak rate and Subject to Sauda updated as of Today. Glenmark Life Sciences IPO Grey Market Premium has been started with Low Premium Rates, We need to wait for the rates to change with the Market Sentiment in a few days or to Stabilize the Rates.
Glenmark Life Sciences is a major developer and manufacturer of selective high-value, non-personalized active pharmaceutical ingredients (APIs) in older therapeutic areas. Glenmark Life sciences supply over 130 APIs to its 700+ customers located in 65 countries around the world. It has 3 API-producing units in India and has an annual production capacity of over 450 metric tonnes.
Glenmark Life Sciences IPO Issue size of ₹1513.60 Crores, in which Fresh Issue of ₹1060 Crores and Offer For Sale of ₹453.60 Crores and issue price band has been fixed at ₹695-₹720 Per Share. The Glenmark Life Sciences IPO is to be listed Soon on NSE and BSE.
What is Glenmark Life Sciences IPO GMP Today?
■ The Glenmark Life Sciences IPO GMP Today Or Grey Market Premium is ₹75-₹85.
What is Glenmark Life Sciences IPO Kostak Rates Today?
■ The Glenmark Life Sciences IPO Kostak rate is ₹0.
What is Glenmark Life Sciences IPO Subject to Sauda Price Today?
■ The Glenmark Life Sciences IPO Subject to Sauda rates is ₹0.
Glenmark Life Sciences IPO Approximately Returns?
■ The Glenmark Life Sciences IPO’s approximate return is 15%-20%. And it can also change according to the Market Sentiment.
Glenmark Life Sciences IPO GMP, Kostak, Subject to Sauda :
| Date | GMP | Kostak | Subject |
| 6 Aug 2021 | List – ₹750 | ₹0 | ₹0 |
| 5 Aug 2021 | ₹75-₹85 | ₹0 | ₹0 |
| 4 Aug 2021 | ₹85-₹90 | ₹0 | ₹0 |
| 3 Aug 2021 | ₹90-₹100 | ₹300 | ₹2000 |
| 2 Aug 2021 | ₹90-₹100 | ₹300 | ₹2000 |
| 1 Aug 2021 | ₹140-₹150 | ₹300 | ₹2800 |
| 31 July 2021 | ₹140-₹150 | ₹300 | ₹2800 |
| 30 July 2021 | ₹140-₹150 | ₹300 | ₹2800 |
| 29 July 2021 | ₹120-₹130 | ₹300 | ₹2800 |
| 28 July 2021 | ₹110-₹120 | ₹300 | ₹2800 |
| 27 July 2021 | ₹100-₹110 | ₹300 | ₹3000 |
| 26 July 2021 | ₹200-₹210 | ₹350 | ₹3000 |
| 25 July 2021 | ₹180-₹200 | ₹300 | ₹2500 |
| 24 July 2021 | ₹120-₹130 | ₹300 | ₹2500 |
| 23 July 2021 | ₹120-₹130 | ₹300 | ₹2500 |
| 22 July 2021 | ₹180-₹190 | ₹400 | ₹4000 |
| 21 July 2021 | ₹200-₹210 | ₹450 | ₹4500 |
| 20 July 2021 | ₹0 | ₹0 | ₹0 |
| 19 July 2021 | ₹0 | ₹0 | ₹0 |
| 18 July 2021 | ₹0 | ₹0 | ₹0 |
| 17 July 2021 | ₹0 | ₹0 | ₹0 |
| 16 July 2021 | ₹0 | ₹0 | ₹0 |
| 15 July 2021 | ₹0 | ₹0 | ₹0 |
| 14 July 2021 | ₹0 | ₹0 | ₹0 |
| 13 July 2021 | ₹0 | ₹0 | ₹0 |
| 12 July 2021 | ₹0 | ₹0 | ₹0 |
| 11 July 2021 | ₹0 | ₹0 | ₹0 |
| 10 July 2021 | ₹0 | ₹0 | ₹0 |
| 9 July 2021 | ₹0 | ₹0 | ₹0 |
| 8 July 2021 | ₹0 | ₹0 | ₹0 |
| 7 July 2021 | ₹0 | ₹0 | ₹0 |
| 6 July 2021 | ₹0 | ₹0 | ₹0 |
| 5 July 2021 | ₹0 | ₹0 | ₹0 |
| 4 July 2021 | ₹0 | ₹0 | ₹0 |
| 3 July 2021 | ₹0 | ₹0 | ₹0 |
Glenmark Life Sciences IPO Shares Offer :
A total of 210,22,222 shares are to be bid for the public issue by Glenmark Life Sciences IPO with 147,22,222 for Fresh issue and 63,00,000 for an offer for sale Shares.
| Category | Shares Offers | Amount |
|---|---|---|
| Fresh issue : | 147,22,222 | ₹1060 Cr |
| Offer For Sale : | 63,00,000 | ₹453.60 Cr |
| Total : | 210,22,222 | ₹1513.60 Cr |
Glenmark Life Sciences IPO Reservation :
Glenmark Life Sciences IPO Total Reservation of 210,22,222 shares are to be bid for the public issue by Glenmark Life Sciences IPO with 10,511,111 for QIB and 31,53,333 for NII 73,57,777 For RII & – Shares EMP.
| Category | Reservation | Shares | Amount |
|---|---|---|---|
| QIB : | 50 % | 10,511,111 | ₹756.80 Cr |
| NII : | 15 % | 31,53,333 | ₹227.04 Cr |
| RII : | 35 % | 73,57,777 | ₹529.76 Cr |
| EMP : | – % | – | ₹ |
| Total : | 100 % | 210,22,222 | ₹1513.60 |
Glenmark Life Sciences IPO Date & Price Band & Details :
| IPO Open : | 27 July 2021 |
| IPO Close : | 29 July 2021 |
| IPO Size : | ₹1513.60. Cr |
| Face Value : | ₹2 Rs. Equity Share |
| Price Band : | ₹695 – ₹720 Per Share |
| Listing On : | BSE, NSE |
| Issue Size : | ₹1513.60. Cr |
| Fresh Issue : | ₹1060. Cr |
| Offer For Sale : | ₹453.60. Cr |
Glenmark Life Sciences IPO Market Lot :
Glenmark Life Sciences IPO Minimum Market lot is 1 Lot with 20 shares with ₹14,400 Application amount. The retail investors can apply up to 13 lots with 260 Shares or ₹187,200 amounts.
| Minimum Lot Size : | 1 Lot |
| Minimum Share : | 20 |
| Minimum Amount : | ₹14,400 |
| Maximum Lot Size : | 13 Lot |
| Maximum shares : | 260 |
| Maximum Amount : | ₹187,200 |
Glenmark Life Sciences IPO Dates :
Glenmark Life Sciences IPO Open Date is 27 July 2021 and close date 29 July 2021. The allotment will be finalized on 3 Aug 2021 and the IPO may list on 6 Aug 2021.
| Open Date : | 27 July 2021 |
| Close Date : | 29 July 2021 |
| Allotment Date : | 3 Aug 2021 |
| Refund Date : | 4 Aug 2021 |
| Share Credit Date : | 5 Aug 2021 |
| Listing Date : | 6 Aug 2021 |
Glenmark Life Sciences Company Financial Report (Cr) :
| Year | Revenue | Expense | P&L |
| 2020 | ₹15,493.03 | ₹11,282.36 | ₹3,130.98 |
| 2019 | ₹8,868.65 | ₹6,585.68 | ₹1,955.92 |
| 2018 | ₹2.48 | ₹2.61 | ₹4.34 |
About Glenmark Life Sciences Company
We are a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (“APIs”) in chronic therapeutic areas, including cardiovascular disease (“CVS”), central nervous system disease (“CNS”), pain management, and diabetes (Source: Frost & Sullivan Report). We also manufacture and sell APIs for gastro-intestinal disorders, anti-infectives, and other therapeutic areas. Our API portfolio comprises specialized and profitable products, including niche and technically complex molecules, which we believe reflects our capability to branch into other high-value products.
| Read also:- Share Buyback List 2021 |
We have a strong market share in select specialized APIs such as Telmisartan (anti-hypertensive), Atovaquone (anti-parasitic), Perindopril (antihypertensive), Teneligliptin (diabetes), Zonisamide (CNS), and Adapalene (dermatology) (Source: Frost & Sullivan Report). We are also increasingly providing contract development and manufacturing operations (“CDMO”) services to a range of multinational and specialty pharmaceutical companies.
We are a research and development (“R&D”)-driven API manufacturer, focused on undertaking dedicated R&D in our existing products and in areas where we believe there is growth potential in the future. We believe that maintaining high standards of process innovation and quality in our R&D and manufacturing operations is critical to our brand and the maintenance of long-term relationships with our customers.
Glenmark Life Sciences IPO GMP FAQs :
How much is Glenmark Life Sciences IPO GMP Today?
Glenmark Life Sciences IPO GMP Today is ₹75-₹85.
How much is Glenmark Life Sciences IPO Grey Market Premium?
Glenmark Life Sciences IPO is Grey Market Premium ₹75-₹85.
What is Glenmark Life Sciences IPO Kostak Rate?
Glenmark Life Sciences IPO Kostak Rate is ₹0.
What is Glenmark Life Sciences IPO Subject to Sauda?
Glenmark Life Sciences IPO Subject to Deals is ₹0.
What are Glenmark Life Sciences IPO Approx Returns?
Glenmark Life Sciences IPO approx Returns is 15%-20%. And it can also change according to the Market Sentiment.
| Glenmark Life Sciences IPO Details: Click Here Glenmark Life Sciences IPO Subscription: Click Here Glenmark Life Sciences IPO Allotment: Click Here Glenmark Life Sciences IPO Listing: Click Here |
All Glenmark Life Sciences IPO-related links are available here. If you want to know the details then click on Click Here Link.
Disclaimer: STOCK MARKET INVESTMENTS ARE SUBJECT TO MARKET RISKS, READ ALL SCHEME RELATED DOCUMENTS CAREFULLY.